Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13i Safety and Immunogenicity in Healthy People
NCT04841369Phase 3Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of iPneucia in pneumococcal infection, sponsored by CanSino Biologics Inc.. Started Apr 2021; status: completed.
02
Drugs
iPneucia
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT04841369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841369.